ReviewPathology international2023
Underlying mechanisms of thrombus formation/growth in atherothrombosis and deep vein thrombosis.
Review in Pathology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 40 citations in OpenAlex.
- Picropodophyllotoxin Suppresses Factor Xa Activity, Platelet Aggregation, and Arterial Thrombosis.Biomolecules · 2026Article
- A murine stable thrombosis model enabling therapeutic evaluation of antithrombotic drugs.Blood vessels, thrombosis & hemostasis · 2026Article
- Diagnostic Performance of Immature Platelet Fraction in Patients with Suspected Deep Vein Thrombosis.Healthcare (Basel, Switzerland) · 2026Article
- Potential Role of Polyphenols in Platelet Aggregation and Blood Coagulation.Journal of cardiovascular development and disease · 2026Review
- A case report of distal coronary artery spasm overlapping a calcified nodule: a rare mechanism of acute coronary syndrome.European heart journal. Case reports · 2026Article
- Development and validation of a deep vein thrombosis risk assessment tool for surgical patients aged 75 years and older.BMC geriatrics · 2026Article
- Computational and Molecular Dynamics Insights into the Antithrombotic Mechanism of Triterpenes Derived fromMolecules (Basel, Switzerland) · 2026Article
- Thrombin Generation Induced by Complement Component C1q Interaction With the Receptor for the Globular Head of C1q on Adventitial Fibroblasts and Vascular Smooth Muscle Cells.Immunity, inflammation and disease · 2026Article
- Risk factors for deep venous thrombosis in spontaneous intracerebral hemorrhage and their long-term prognostic implications.Open medicine (Warsaw, Poland) · 2026Article
- Delivery of TCM Monomers Using Blood Cell Membrane Coated Biomimetic Nanoparticles to Target CVD.International journal of nanomedicine · 2026Review
- Preparation and evaluation of a small-diameter vascular graft with dual anticoagulant and anticalcification functions.Regenerative biomaterials · 2026Article
- Haemostasis and the Need for Antithrombotics: An Introduction.Handbook of experimental pharmacology · 2026Review
- From Vascular Dysfunction to Atherothrombosis: The Pivotal Role of Eicosanoids and Their Receptors in Platelet and Endothelial Imbalance: A Scoping Review.International journal of molecular sciences · 2025Article
- Review
- Prediction model for leaflet thrombosis in patients undergoing transcatheter aortic valve implantation: the EFFORT study.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Observational
- Rapid-Onset Venous Thrombosis After Tibia Fracture: A Case Report.The American journal of case reports · 2025Article
- Genetic Risk Profiles for Atherosclerosis and Venous Thromboembolism in Azorean and Mainland Portuguese Populations: A Comparative Analysis.Current issues in molecular biology · 2025Article
- Nanomedicine in cardiovascular and cerebrovascular diseases: targeted nanozyme therapies and their clinical potential and current challenges.Journal of nanobiotechnology · 2025Review
- Targeted codelivery of nitric oxide and hydrogen sulfide for enhanced antithrombosis efficacy.Bioactive materials · 2025Article
- Platelets and diseases: signal transduction and advances in targeted therapy.Signal transduction and targeted therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Thrombosis remains a leading cause of death worldwide despite technological advances in prevention, diagnosis, and treatment. The traditional view of arterial thrombus formation is that it is a platelet-dependent process, whereas that of venous thrombus formation is a coagulation-dependent process. Current pathological and basic studies on atherothrombosis and venous thrombosis have revealed the diverse participation of platelet and coagulation activation mechanisms in both thrombus initiation and growth processes during clinical thrombotic events. Atherosclerotic plaque cell-derived tissue factor contributes to fibrin formation and platelet aggregation. The degree of plaque disruption and a blood flow alteration promote atherothrombotic occlusion. While blood stasis/turbulent flow due to luminal stenosis itself initiates venous thrombus formation. The coagulation factor XI-driven propagation phase of blood coagulation plays a major role in venous thrombus growth, but a minor role in hemostasis. These lines of evidence indicate that atherothrombosis onset is affected by the thrombogenic potential of atherosclerotic plaques, the plaque disruption size, and an alteration in blood flow. Upon onset of venous thrombosis, enhancement of the propagation phase of blood coagulation under blood stasis and a hypercoagulable state contribute to large thrombus formation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.